

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA **复星医药**

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

SECOND SUPPLEMENTAL ANNOUNCEMENT TO THE CIRCULAR OF THE COMPANY DATED 31 OCTOBER 2022

References are made to (i) the circular of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) dated 31 October 2022 (the “**Circular**”) in relation to, among other things, the Renewed Financial Services Agreement which is subject to Independent Shareholders’ approval pursuant to Chapter 14A of the Hong Kong Listing Rules, and (ii) the supplemental announcement to the Circular of the Company dated 31 October 2022 (the “**First Supplemental Announcement**”) in relation to the undertaking letter issued by Fosun High Tech to the Company (the “**Fosun High Tech Undertaking Letter**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Circular.

The Board announces that, on 2 November 2022, it received an undertaking letter (the “**Fosun Finance Undertaking Letter**”) from Fosun Finance to the Company. Pursuant to the Fosun Finance Undertaking Letter, Fosun Finance has undertaken that, during the service term of the Renewed Financial Services Agreement, the deposits placed by the Company and its subsidiaries with Fosun Finance under the Renewed Financial Services Agreement will primarily be used to provide comprehensive credit services, including but not limited to loan, entrusted loan, note and discount, to the Company and its subsidiaries.

No amendment has been made to the terms of the Renewed Financial Services Agreement entered into by the Company and Fosun Finance as a result of the Fosun Finance Undertaking Letter, and the Board confirms that its recommendations as set out in the “Letter from the Board” of the Circular remains unchanged. The Company has also notified Yue Xiu Capital, the Independent Financial Adviser, and the Independent Board Committee of the above, both of whom have confirmed that the Fosun Finance Undertaking Letter and the Fosun High Tech Undertaking Letter (whether considered separately or jointly) do not change their respective conclusions and recommendations to the Independent Shareholders as to voting on the relevant resolution as set out in the Circular with respect to the transactions contemplated under the Renewed Financial Services Agreement (as respectively set out in the “Letter from the Independent Financial Adviser in respect of the Renewed Financial Services Agreement” and “Letter from the Independent Board Committee in respect of the Renewed Financial Services Agreement” of the Circular).

Save as disclosed above, all other information in the Circular and the First Supplemental Announcement remains unchanged. This announcement is supplemental to and should be read in conjunction with the Circular and the First Supplemental Announcement.

By Order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
2 November 2022

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

** For identification purpose only*